In a phase 3 clinical trial, this AAV9 vector has found success in intravenously delivering the SMA1 transgeneeffectively restoring motor functions in SMA patients [157, 158]
Kopetz S , Grothey A, Yaeger R, Cuyle PA, Huijberts S, M Schellens JH, Elez E, Fakih M, Viladot CM, Peeters M, Desai J, Yoshino T, Ciardiello F, Wasan HS, Maharry K, Christy-Bittel J, Gollerkeri A, Cutsem EV, Tabernero J
Some sequences are problematic in solid-phase peptide synthesis or cleavage and are best avoided
Working with a healthcare provider experienced in GLP-1 therapy ensures appropriate patient selection and dosing
Together, these effects raise the chance of developing kidney stones
While its not exactly an epiphany or eureka moment, the realization to keep in mind is that t he gut talks to the brain and the immune system